Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of liposome-encapsulated ruthenium polypyridine complex and its application

A ruthenium polypyridine and liposome technology, applied in the field of ruthenium polypyridine complexes encapsulated by liposomes, can solve the problems of high toxicity, physical damage of cancer patients, etc., and achieves low toxicity, low toxic and side effects, and easy absorption. Effect

Active Publication Date: 2021-08-06
WENZHOU INST OF BIOMATERIALS & ENG
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, cisplatin has strong side effects, including nephrotoxicity, myelosuppression, neurotoxicity, gastrointestinal toxicity, ototoxicity, etc. It is highly toxic and will cause great damage to the body of cancer patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of liposome-encapsulated ruthenium polypyridine complex and its application
  • A kind of liposome-encapsulated ruthenium polypyridine complex and its application
  • A kind of liposome-encapsulated ruthenium polypyridine complex and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1: A liposome encapsulated ruthenium pyridine complex, comprising the following parts by weight:

[0040] 4 parts of dichloro double (2,2'-gipyridine) ruthenium;

[0041] 2 copies of acetate;

[0042] 100 parts of liposomes;

[0043] 5 copolygense;

[0044] Two antioxidants;

[0045] 3 copies of buffer;

[0046] 2 parts of antibacterial agent;

[0047] 1 stabilizer;

[0048] The adjustment agent includes the following weight part:

[0049] 3 parts of diisopropyl titanate in di (triethanolamine);

[0050] Trimethoxy [2- (7-oxidal dihydrate [4.1.0] hept-3-yl) ethyl] silane 2 parts;

[0051] (3S, 6E, 10S) -6,10-dimethyl-3-isopropylcyclo-6-u-1,4-diketone 2 parts;

[0052] 4 parts of diethyl aliquots.

[0053] The liposome includes the following weight part:

[0054] Oval phospholipids;

[0055] 5 parts of cholesterol;

[0056] Eight of dihydrate phosphate chloride - polyhexanediol;

[0057] 2 parts of polyethylene glycol polylactic acid.

[0058] The lecithin is any of ...

Embodiment 2

[0067] Example 2: A liposome encapsulated ruthenium polypyridine complex, comprising the following parts by weight:

[0068] 4 parts of dichloro double (2,2'-gipyridine) ruthenium;

[0069] 2 copies of acetate;

[0070] 100 parts of liposomes;

[0071] 5 copolygense;

[0072] Two antioxidants;

[0073] 3 copies of buffer;

[0074] 2 parts of antibacterial agent;

[0075] 1 stabilizer;

[0076] The adjustment agent includes the following weight part:

[0077] 3 parts of diisopropyl titanate in di (triethanolamine);

[0078] Trimethoxy [2- (7-oxidal dihydrate [4.1.0] hept-3-yl) ethyl] silane 2 parts;

[0079] (3S, 6E, 10S) -6,10-dimethyl-3-isopropylcyclo-6-u-1,4-diketone 2 parts;

[0080] 4 parts of diethyl aliquots.

[0081] The liposome includes the following weight part:

[0082] Oval phospholipids;

[0083] 5 parts of cholesterol;

[0084] Eight of dihydrate phosphate chloride - polyhexanediol;

[0085] 2 parts of polyethylene glycol polylactic acid.

[0086] The lecithin is any...

Embodiment 3

[0097] Example 3: A liposome encapsulated ruthenium polypyridine complex, comprising the following parts by weight:

[0098] 4 parts of dichloro double (2,2'-gipyridine) ruthenium;

[0099] 2 copies of acetate;

[0100] 100 parts of liposomes;

[0101] 5 copolygense;

[0102] Two antioxidants;

[0103] 3 copies of buffer;

[0104] 2 parts of antibacterial agent;

[0105] 1 stabilizer;

[0106] The adjustment agent includes the following weight part:

[0107] 3 parts of diisopropyl titanate in di (triethanolamine);

[0108] Trimethoxy [2- (7-oxidal dihydrate [4.1.0] hept-3-yl) ethyl] silane 2 parts;

[0109] (3S, 6E, 10S) -6,10-dimethyl-3-isopropylcyclo-6-u-1,4-diketone 2 parts;

[0110] 4 parts of diethyl aliquots.

[0111] The liposome includes the following weight part:

[0112] Oval phospholipids;

[0113] 5 parts of cholesterol;

[0114] Eight of dihydrate phosphate chloride - polyhexanediol;

[0115] 2 parts of polyethylene glycol polylactic acid.

[0116] The lecithin is any...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a liposome-encapsulated ruthenium polypyridine complex and its application. By using dichlorobis(2,2'-bipyridine) ruthenium and ruthenium acetate as anticancer metal complexes, compared with cis Platinum and ruthenium complexes have low toxicity and side effects, are easy to absorb and excrete quickly, and can inhibit tumor growth and metastasis; at the same time, they are encapsulated with liposomes, and by adding blending agents, antioxidants, buffers, antibacterial agents and stabilizers , wherein the blending agent has selected bis(triethanolamine) diisopropyl titanate, trimethoxy[2-(7-oxabicyclo[4.1.0]heptyl-3-yl)ethyl]silane, (3S, 6E,10S)‑6,10‑dimethyl‑3‑isopropylcyclodec‑6‑ene‑1,4‑dione and diethylene glycol ether, under the combined action of these substances, can greatly improve The mutual coordination between liposomes and ruthenium complexes makes the final liposome-encapsulated ruthenium polypyridine complexes have good biocompatibility and low toxicity; It can be used as a chemotherapeutic or imaging agent in treatment.

Description

Technical field [0001] The present invention relates to a ruthenium complex, more specifically, involving a liposome encapsulated ruthenopridine complex and its application thereof. Background technique [0002] Cancer is also known as malignant tumors, is a disease caused by the loss of normal regulation and excessive proliferation of body cells. At present, cancer has become one of the major malignant diseases that threaten human deaths in the world; according to statistics, there is one person died in cancer every year of 4-5 people died every year. Treatment of cancer patients is now treated by combining surgery, chemotherapy, and radiotherapy. [0003] Based on metallic anticancer drugs can prevent cancer cells from dividing and causing cancer cell apoptosis by inducing DNA damage and destroying DNA repair processes. The most widely used metal chemotherapeutic drugs are cisplatin, and I was approved by FDA in 1978. It is one of the most clinical use of several chemotherapeut...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/127A61K47/18A61K47/24A61K47/08A61K47/10A61K47/14A61K47/22A61K31/444A61K31/19A61P35/00A61P35/04A61K49/00
CPCA61K9/1271A61K31/444A61K33/24A61K47/08A61K47/10A61K47/14A61K47/18A61K47/22A61K47/24A61K49/0019A61P35/00A61P35/04A61K2300/00
Inventor 钱宇娜沈建良
Owner WENZHOU INST OF BIOMATERIALS & ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products